Find information on thousands of medical conditions and prescription drugs.

Droperidol

Droperidol (Dropletan®) is an antidopaminergic drug used as an antiemetic and antipsychotic. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Droperidol is a butyrophenone, and is a potent D2 (dopamine receptor) antagonist with some histamine and serotonin antagonist activity. It has a central antiemetic action and is frequently used in the treatment of Postoperative nausea and vomiting in adult doses as low as 0.625 or 1.25 mg.

It has also been used as an anti-psychotic in doses as high as 10mg i.m.

In 2001, the FDA changed the labeling requirements for droperidol injection, to include a so-called "Black Box Warning", citing concerns of QT prolongation and Torsades de pointes. The evidence for this is disputed, with less than 20 reported cases of torsades in 30 years and most of those having received doses in excess of 50mg in a 24-hour period. It appears that the QT-prolongation is a dose-related effect and that in low doses, droperidol is not a significant risk.

Read more at Wikipedia.org


[List your site here Free!]


Drug-induced prolongation of the QT interval
From American Family Physician, 1/1/05 by Bill Zepf

The most common reason for removing a prescription drug from the U.S. market in the past decade has been prolongation of the QT interval. There is an increased risk for the development of torsades de pointes, a potentially fatal arrhythmia, when the QT interval is prolonged. Roden reviewed the drugs most commonly implicated in QT prolongation and the clinical factors that increase the risk of torsades de pointes.

Medication-induced QT prolongation was first recognized with the use of quinidine in the 1920s. Roden lists other drugs that also are implicated in prolongation of the QT interval and may cause torsades de pointes (Table 1). Use of these medications, especially when a congenital QT prolongation syndrome or other clinical risk factor is present, increases the chance that torsades de pointes may develop (Table 2). Because the risk of torsades de pointes is sufficiently high at typical clinical dosages of sotalol, dofetilide, and ibutilide, the review author recommends inhospital cardiac monitoring when therapy with these agents is initiated.

The risk of torsades de pointes is not related linearly to the degree of QT prolongation, although any drug that prolongs the QT interval beyond 500 msec is thought to confer an elevated risk. Heart rate exerts an important effect on the risk for associated torsades de pointes, with a greater propensity for developing the arrhythmia when bradycardia is present.

QT prolongation occurs when a drug or congenital syndrome affects ion channels in cardiac cells and leads to prolongation of the action potential during depolarization. This step may lead to a reduced reserve for normal repolarization, which then increases the risk of developing torsades de pointes. However, these known links do not explain completely the risk of torsades de pointes. Amiodarone often causes QT prolongation beyond 500 msec, yet rarely causes torsades de pointes. Terfenadine was removed from the market because of associated episodes of torsades de pointes, yet therapeutic dosages only extended the QT interval by 6 msec. The degree of QT prolongation caused by a given medication can be influenced by the concomitant use of other agents that inhibit drug elimination. Examples cited by Roden include erythromycin, clarithromycin, ketoconazole, itraconazole, amiodarone, quinidine, and a number of antidepressants and antiretrovirals.

The author concludes that when physicians need to use a medication known to have the effect of prolonging the QT interval, a review of other risk factors that may increase the likelihood that torsades de pointes will develop is recommended. Therefore, an elderly woman with heart failure who also takes medications that might indirectly lead to increased risk (e.g., diuretic use causing hypokalemia) would be a particularly risky candidate for use of a drug that prolongs the QT interval. Close clinical and electrocardiographic monitoring would be prudent during treatment.

Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med March 4, 2004;350:1013-22.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Droperidol
Home Contact Resources Exchange Links ebay